BIOMAT Database Logo BIOMAT Database Logo

Drug-induced CD30+ T cell pseudolymphoma. 2009

Shoko Fukamachi, and Kazunari Sugita, and Yu Sawada, and Toshinori Bito, and Motonobu Nakamura, and Yoshiki Tokura

UI MeSH Term Description Entries
D006973 Hypertension Persistently high systemic arterial BLOOD PRESSURE. Based on multiple readings (BLOOD PRESSURE DETERMINATION), hypertension is currently defined as when SYSTOLIC PRESSURE is consistently greater than 140 mm Hg or when DIASTOLIC PRESSURE is consistently 90 mm Hg or more. Blood Pressure, High,Blood Pressures, High,High Blood Pressure,High Blood Pressures
D008297 Male Males
D003875 Drug Eruptions Adverse cutaneous reactions caused by ingestion, parenteral use, or local application of a drug. These may assume various morphologic patterns and produce various types of lesions. Dermatitis Medicamentosa,Dermatitis, Adverse Drug Reaction,Maculopapular Drug Eruption,Maculopapular Exanthem,Morbilliform Drug Reaction,Morbilliform Exanthem,Drug Eruption,Drug Eruption, Maculopapular,Drug Eruptions, Maculopapular,Drug Reaction, Morbilliform,Drug Reactions, Morbilliform,Eruption, Drug,Eruption, Maculopapular Drug,Eruptions, Drug,Eruptions, Maculopapular Drug,Exanthem, Maculopapular,Exanthem, Morbilliform,Exanthems, Maculopapular,Exanthems, Morbilliform,Maculopapular Drug Eruptions,Maculopapular Exanthems,Morbilliform Drug Reactions,Morbilliform Exanthems,Reaction, Morbilliform Drug,Reactions, Morbilliform Drug
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly
D000959 Antihypertensive Agents Drugs used in the treatment of acute or chronic vascular HYPERTENSION regardless of pharmacological mechanism. Among the antihypertensive agents are DIURETICS; (especially DIURETICS, THIAZIDE); ADRENERGIC BETA-ANTAGONISTS; ADRENERGIC ALPHA-ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CALCIUM CHANNEL BLOCKERS; GANGLIONIC BLOCKERS; and VASODILATOR AGENTS. Anti-Hypertensive,Anti-Hypertensive Agent,Anti-Hypertensive Drug,Antihypertensive,Antihypertensive Agent,Antihypertensive Drug,Anti-Hypertensive Agents,Anti-Hypertensive Drugs,Anti-Hypertensives,Antihypertensive Drugs,Antihypertensives,Agent, Anti-Hypertensive,Agent, Antihypertensive,Agents, Anti-Hypertensive,Agents, Antihypertensive,Anti Hypertensive,Anti Hypertensive Agent,Anti Hypertensive Agents,Anti Hypertensive Drug,Anti Hypertensive Drugs,Anti Hypertensives,Drug, Anti-Hypertensive,Drug, Antihypertensive,Drugs, Anti-Hypertensive,Drugs, Antihypertensive
D012867 Skin The outer covering of the body that protects it from the environment. It is composed of the DERMIS and the EPIDERMIS.
D017311 Amlodipine A long-acting dihydropyridine calcium channel blocker. It is effective in the treatment of ANGINA PECTORIS and HYPERTENSION. Amlodipine Besylate,Amlodipine Maleate,Amlodipine Maleate (1:1),Amlodipine, (+-)-Isomer,Amlodipine, (+-)-Isomer, Maleate (1:1),Amlodipine, (R)-Isomer,Amlodipine, (S)-Isomer, Maleate (1:1),Amlodis,Amlor,Astudal,Istin,Norvasc
D017730 Ki-1 Antigen A member of the tumor necrosis factor receptor superfamily that may play a role in the regulation of NF-KAPPA B and APOPTOSIS. It is found on activated T-LYMPHOCYTES; B-LYMPHOCYTES; NEUTROPHILS; EOSINOPHILS; MAST CELLS and NK CELLS. Overexpression of the Ki-1 antigen in hematopoietic malignancies make it clinically useful as a biological tumor marker. Signaling of the receptor occurs through its association with TNF RECEPTOR-ASSOCIATED FACTORS. Antigens, CD30,Antigens, Ki-1,Ber-H2 Antigens,CD30 Antigens,Ki-1 Antigens,Tumor Necrosis Factor Receptor Superfamily, Member 8,Ber-H2 Antigen,CD30 Antigen,TNFRSF8 Receptor,Antigen, Ber-H2,Antigen, CD30,Antigen, Ki-1,Antigens, Ber-H2,Antigens, Ki 1,Ber H2 Antigen,Ber H2 Antigens,Ki 1 Antigen,Ki 1 Antigens,Receptor, TNFRSF8
D019310 Pseudolymphoma A group of disorders having a benign course but exhibiting clinical and histological features suggestive of malignant lymphoma. Pseudolymphoma is characterized by a benign infiltration of lymphoid cells or histiocytes which microscopically resembles a malignant lymphoma. (From Dorland, 28th ed & Stedman, 26th ed) Hyperplasia, Reactive Lymphoid,Lymphocytoma,Lymphoid Hyperplasia, Reactive,Hyperplasias, Reactive Lymphoid,Lymphocytomas,Lymphoid Hyperplasias, Reactive,Pseudolymphomas,Reactive Lymphoid Hyperplasia,Reactive Lymphoid Hyperplasias

Related Publications

Shoko Fukamachi, and Kazunari Sugita, and Yu Sawada, and Toshinori Bito, and Motonobu Nakamura, and Yoshiki Tokura
CD30-positive T-cell pseudolymphoma induced by amlodipine.
December 2008, Journal of the European Academy of Dermatology and Venereology : JEADV,
Shoko Fukamachi, and Kazunari Sugita, and Yu Sawada, and Toshinori Bito, and Motonobu Nakamura, and Yoshiki Tokura
Papular CD30+ T-cell pseudolymphoma induced by S-1.
February 2022, The Journal of dermatology,
Shoko Fukamachi, and Kazunari Sugita, and Yu Sawada, and Toshinori Bito, and Motonobu Nakamura, and Yoshiki Tokura
CD30-positive T-cell-rich pseudolymphoma induced by gold acupuncture.
May 2002, The British journal of dermatology,
Shoko Fukamachi, and Kazunari Sugita, and Yu Sawada, and Toshinori Bito, and Motonobu Nakamura, and Yoshiki Tokura
An instructive case of amlodipine-induced reversible granulomatous CD30+ T-cell pseudolymphoma.
August 2020, The Australasian journal of dermatology,
Shoko Fukamachi, and Kazunari Sugita, and Yu Sawada, and Toshinori Bito, and Motonobu Nakamura, and Yoshiki Tokura
Cutaneous intravascular CD30+ T-cell pseudolymphoma occurring in a regressing keratoacanthoma.
April 2018, Journal of cutaneous pathology,
Shoko Fukamachi, and Kazunari Sugita, and Yu Sawada, and Toshinori Bito, and Motonobu Nakamura, and Yoshiki Tokura
[Drug-induced pseudolymphoma].
April 1980, Revista clinica espanola,
Shoko Fukamachi, and Kazunari Sugita, and Yu Sawada, and Toshinori Bito, and Motonobu Nakamura, and Yoshiki Tokura
[Drug induced pseudolymphoma].
May 1978, Zeitschrift fur Hautkrankheiten,
Shoko Fukamachi, and Kazunari Sugita, and Yu Sawada, and Toshinori Bito, and Motonobu Nakamura, and Yoshiki Tokura
Drug induced pseudolymphoma.
July 2018, Seminars in diagnostic pathology,
Shoko Fukamachi, and Kazunari Sugita, and Yu Sawada, and Toshinori Bito, and Motonobu Nakamura, and Yoshiki Tokura
Gemcitabine-associated CD8+ CD30+ pseudolymphoma.
October 2001, The British journal of dermatology,
Shoko Fukamachi, and Kazunari Sugita, and Yu Sawada, and Toshinori Bito, and Motonobu Nakamura, and Yoshiki Tokura
Drug-induced pseudolymphoma syndrome.
January 1995, Indian journal of dermatology, venereology and leprology,
Copied contents to your clipboard!